CTR20262758 SY-12321 Anaplastic Large-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262758 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262758 is a hot trial to watch
Anaplastic Large-Cell Lymphoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262758 is notable because it evaluates SY-12321 in a Phase 1 design sponsored by Shouyao Holdings (Beijing) Co. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262758 |
| Official title | 一项在ALK阳性晚期恶性肿瘤患者中评价SY-12321安全性、耐受性、药代动力学及初步疗效的开放性、多中心Ⅰ/Ⅱ期临床试验 |
| Phase / status | Phase 1 / 进行中 （尚未招募） |
| Intervention | SY-12321 |
| Sponsor | Shouyao Holdings (Beijing) Co. Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 整个研究期间 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1 study of SY-12321 in Anaplastic Large-Cell Lymphoma.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (整个研究期间) — SY-12321治疗期间出现的TEAE、ADR、SAE及SAR的发生率及严重程度
- Primary endpoint (整个研究期间) — SY-12321治疗期间出现的异常实验室检查值（血常规、血生化、凝血功能、尿常规等）和生命体征测量值变化
- Primary endpoint (剂量爬坡阶段给药第1个周期内（即首次给药后28天内，包括7天单次给药观察期+21天连续给药观察期）) — SY-12321治疗后出现的剂量限制性毒性（DLT）
- Primary endpoint (剂量递增阶段) — MTD
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: SY-12321 is indexed as Chemical drugs, with target ALK, mechanism ALK inhibitors, and global highest development status Phase 1.
Company & Deal Intelligence MCP profile: Shouyao Holdings (Beijing) Co. Ltd. is resolved to a normalized organization record in Beijing Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262758 provides a focused lens on Anaplastic Large-Cell Lymphoma development. Its value will be determined by whether SY-12321 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
